Shiva Dibaj

714 total citations
25 papers, 225 citations indexed

About

Shiva Dibaj is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Shiva Dibaj has authored 25 papers receiving a total of 225 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 7 papers in Surgery. Recurrent topics in Shiva Dibaj's work include Prostate Cancer Treatment and Research (10 papers), PARP inhibition in cancer therapy (6 papers) and Head and Neck Cancer Studies (5 papers). Shiva Dibaj is often cited by papers focused on Prostate Cancer Treatment and Research (10 papers), PARP inhibition in cancer therapy (6 papers) and Head and Neck Cancer Studies (5 papers). Shiva Dibaj collaborates with scholars based in United States, United Kingdom and Canada. Shiva Dibaj's co-authors include Graham Warren, James R. Marshall, Alan D. Hutson, Carolyn Dresler, K. Michael Cummings, Anurag K. Singh, Nobuyuki Hinata, Mihai Merzianu, Hassan Arshad and Anna E. Płatek and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and Annals of Oncology.

In The Last Decade

Shiva Dibaj

24 papers receiving 224 citations

Peers

Countries citing papers authored by Shiva Dibaj

Since Specialization

Citations

This map shows the geographic impact of Shiva Dibaj's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shiva Dibaj with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shiva Dibaj more than expected).

Fields of papers citing papers by Shiva Dibaj

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shiva Dibaj. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shiva Dibaj. The network helps show where Shiva Dibaj may publish in the future.

Co-authorship network of co-authors of Shiva Dibaj

This figure shows the co-authorship network connecting the top 25 collaborators of Shiva Dibaj. A scholar is included among the top collaborators of Shiva Dibaj based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shiva Dibaj. Shiva Dibaj is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE Trial 2025 ·European Urology Oncology ·Kim N., Elena Castro, G. Attard, Matthew R. Smith, Shahneen Sandhu, Eleni Efstathiou, Guilhem Roubaud, Eric J. Small, (unknown), Dana E. Rathkopf, Marniza Saad, Howard Gurney, Wonho Jung, Won Kim, Shiva Dibaj, Daphne Wu, Jenny Zhang, Angela Lopez‐Gitlitz, Peter Francis, David Olmos	1
2	Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes. 2025 ·Journal of Clinical Oncology ·Gerhardt Attard, Neeraj Agarwal, Julie N. Graff, Shahneen Sandhu, Eleni Efstathiou, Mustafa Özgüroğlu, Andrea Juliana Gomes, (unknown), Hong Luo, Heather H. Cheng, Won Bae Kim, (unknown), Daneen Schaeffer, Shiva Dibaj, Susan Li, Fei Shen, Suneel Mundle, David Olmos, Kim N., Dana E. Rathkopf, (unknown)	6
3	Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE Trial 2024 ·European Urology ·Dana E. Rathkopf, Guilhem Roubaud, Kim N., Eleni Efstathiou, Gerhardt Attard, David Olmos, Eric J. Small, Marniza Saad, Elena Castro, Won Kim, Daphne Wu, (unknown), Shiva Dibaj, Jenny Zhang, Peter Francis, Matthew R. Smith	5
4	Patient-reported outcomes (PRO) in patients (pts) with BRCA1/2-altered metastatic castration-resistant prostate cancer (mCRPC) receiving niraparib (NIRA) with abiraterone acetate and prednisone (AAP): Results from MAGNITUDE study. 2024 ·Journal of Clinical Oncology ·Dana E. Rathkopf, Guilhem Roubaud, Kim N., Eleni Efstathiou, Gerhardt Attard, David Olmos, Eric J. Small, Marniza Saad, Elena Castro, Won Kim, Daphne Wu, (unknown), Shiva Dibaj, Jenny Zhang, Peter Francis, Matthew R. Smith	2
5	LBA85 Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of MAGNITUDE 2023 ·Annals of Oncology ·(unknown), Elena Castro, Gerhardt Attard, Matthew R. Smith, Shahneen Sandhu, Eleni Efstathiou, Guilhem Roubaud, Eric J. Small, (unknown), Dana E. Rathkopf, Marniza Saad, Howard Gurney, Wonho Jung, Gary Mason, Shiva Dibaj, Daphne Wu, B. Diorio, Angela Lopez‐Gitlitz, (unknown), David Olmos	6
6	Impact of run-in treatment with abiraterone acetate and prednisone (AAP) in the MAGNITUDE study of niraparib (NIRA) and AAP in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations. 2023 ·Journal of Clinical Oncology ·Elena Castro, Kim N., Shahneen Sandhu, David Olmos, Gerhardt Attard, Marniza Saad, Andrea Juliana Gomes, Dana E. Rathkopf, Matthew R. Smith, Taek Won Kang, Felipe Melo Cruz, Umberto Basso, Gary Mason, Adam del Corral, Shiva Dibaj, Daphne Wu, Brooke Diorio, (unknown), Deniz Tural, Eric J. Small	4
7	Health-related Quality of Life at the SPARTAN Final Analysis of Apalutamide for Nonmetastatic Castration-resistant Prostate Cancer Patients Receiving Androgen Deprivation Therapy 2021 ·European Urology Focus ·Stéphane Oudard, Boris Hadaschik, Fred Saad, David Cella, Ethan Basch, Julie N. Graff, Hiroji Uemura, Shiva Dibaj, Susan Li, Sabine Brookman‐May, Peter De Porre, Katherine B. Bevans, Jeremiah Trudeau, Eric J. Small, Matthew R. Smith	14
8	Health-related quality of life (HRQoL) and patient-reported outcomes at final analysis of the TITAN study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT). 2021 ·Journal of Clinical Oncology ·Neeraj Agarwal, Simon Chowdhury, Anders Bjartell, Byung Ha Chung, Andrea Juliana Gomes, Robert Given, Álvaro Juárez, Axel S. Merseburger, Mustafa Özgüroğlu, Hirotsugu Uemura, Dingwei Ye, Sabine Brookman‐May, Suneel Mundle, Sharon McCarthy, Florence Lefresne, Shiva Dibaj, Katherine B. Bevans, Kim N., (unknown)	3
9	632P Health-related quality of life (HRQoL) at final analysis of the SPARTAN study of apalutamide (APA) vs placebo (PBO) in patients (pts) with non-metastatic castration-resistant prostate cancer (nmCRPC) receiving androgen deprivation therapy (ADT) 2020 ·Annals of Oncology ·Stéphane Oudard, Boris Hadaschik, Fred Saad, David Cella, Ethan Basch, Paul N. Mainwaring, Julie N. Graff, Shiva Dibaj, S. Li, (unknown), Peter De Porre, Jeremiah Trudeau, Eric J. Small, Mitchell R. Smith	3
10	P3.01-109 Real-World Patient-Reported Outcome Assessment of Patients with Metastatic Non-Small Cell Lung Cancer 2018 ·Journal of Thoracic Oncology ·Loretta A. Williams, Shiva Dibaj, Sheenu Chandwani, (unknown), Qiuling Shi, (unknown), (unknown), Emily Roarty, J. Zhang, (unknown), Jeffery D. Lewis, Thomas Burke, Charles S. Cleeland, Jes Chauviere Lee, Jack A. Roth, (unknown), John V. Heymach, George R. Simon	1
11	Prospective Comparison of Toxicity and Cosmetic Outcome After Accelerated Partial Breast Irradiation With Conformal External Beam Radiotherapy or Single-Entry Multilumen Intracavitary Brachytherapy 2018 ·Practical Radiation Oncology ·Shane R. Stecklein, Simona F. Shaitelman, Gildy V. Babiera, Isabelle Bedrosian, Dalliah M. Black, Matthew T. Ballo, (unknown), Eric A. Strom, Valerie Reed, Tomáš Dvořák, Benjamin D. Smith, Wendy A. Woodward, Karen E. Hoffman, Pamela J. Schlembach, (unknown), Christopher Nelson, Jinzhong Yang, (unknown), Shiva Dibaj, Elizabeth S. Bloom	12
12	Subsite variation in survival of oropharyngeal squamous cell carcinomas 2004 to 2011 2016 ·The Laryngoscope ·Anna E. Płatek, Vijayvel Jayaprakash, Vishal Gupta, David Cohan, Wesley L. Hicks, (unknown), (unknown), Adrienne Groman, Shiva Dibaj, Hassan Arshad, Moni Abraham Kuriakose, Graham Warren, Anurag K. Singh	6
13	Development and Validation of a Quality Assurance Score for Robot-assisted Radical Cystectomy: A 10-year Analysis 2016 ·Urology ·Ahmed A. Hussein, Shiva Dibaj, Nobuyuki Hinata, (unknown), Kathleen A. O’Leary, Boris W. Kuvshinoff, James L. Mohler, Gregory E. Wilding, Khurshid A. Guru	21
14	Development, validation and clinical application of Pelvic Lymphadenectomy Assessment and Completion Evaluation: intraoperative assessment of lymph node dissection after robot‐assisted radical cystectomy for bladder cancer 2016 ·British Journal of Urology ·Ahmed A. Hussein, Nobuyuki Hinata, Shiva Dibaj, Paul May, (unknown), Hassan Abol‐Enein, Ronney Abaza, Daniel Eun, (unknown), James L. Mohler, Piyush K. Agarwal, Kamal S. Pohar, Richard Sarle, Ronald S. Boris, (unknown), Alan D. Hutson, Khurshid A. Guru	13
15	Smoking cessation is associated with improved survival in oropharynx cancer treated by chemoradiation 2016 ·The Laryngoscope ·(unknown), Vijayvel Jayaprakash, Mihai Merzianu, Anna E. Płatek, David Cohan, Wesley L. Hicks, S. Marimuthu, (unknown), Vishal Gupta, Hassan Arshad, Moni Abraham Kuriakose, Shiva Dibaj, James R. Marshall, Mary E. Reid, Graham Warren, Anurag K. Singh	40
16	Identifying Targeted Strategies to Improve Smoking Cessation Support for Cancer Patients 2015 ·Journal of Thoracic Oncology ·Graham Warren, Shiva Dibaj, Alan D. Hutson, K. Michael Cummings, Carolyn Dresler, James R. Marshall	55
17	Reappraisal of Serosal Invasion in Patients With T3 Colorectal Cancer by Elastic Stain: Clinicopathologic Study of 139 Surgical Cases With Special Reference to Peritoneal Elastic Lamina Invasion 2015 ·Archives of Pathology & Laboratory Medicine ·Yukihiro Nakanishi, Charles LeVea, Shiva Dibaj, (unknown), Richard Cheney, Kazunori Kanehira	9
18	Neutrophil to lymphocyte ratio (NLR) as a predictive marker of response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) in EGFR mutation-positive non-small cell lung cancer (NSCLC). 2014 ·Journal of Clinical Oncology ·(unknown), Grace K. Dy, Petr Starostik, Shiva Dibaj	1
19	Randomized Double-Blind, Placebo-Controlled, Multicenter Phase 2 Trial of Selenomethionine as a Modulator of Efficacy and Toxicity of Chemoradiation in Locally-Advanced Squamous Cell Carcinoma of the Head and Neck 2013 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), Michael B. Jameson, (unknown), Shiva Dibaj, Adrienne Groman, Wainwright Jaggernauth, Youcef M. Rustum, Anurag K. Singh	3
20	Cut‐off value of 1‐h, 50‐g glucose challenge test for screening of gestational diabetes mellitus in an Iranian population 2011 ·Journal of obstetrics and gynaecology research ·Samira Behboudi‐Gandevani, (unknown), Shiva Dibaj	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact